Neuraxis shares surge 21.05% premarket after securing major insurer coverage for PENFS therapy, expanding access to 100M lives.

Neuraxis surged 21.05% in premarket trading following the announcement of new medical policy coverage from a major national health insurer for its PENFS technology, expanding access to approximately 100 million covered lives. The coverage, spanning 45 million additional members, underscores the growing clinical and payer recognition of IB-Stim, Neuraxis’s FDA-cleared neuromodulation device for treating functional abdominal pain in pediatric and adult patients. CEO Brian Carrico highlighted the milestone as a catalyst for revenue growth and margin expansion, citing the upcoming Category I CPT code effective January 1, 2026, and integration into national clinical guidelines. The news reinforces the company’s position in addressing an unmet medical need with no FDA-approved drug alternatives for pediatric functional dyspepsia, bolstering investor confidence ahead of broader market adoption.